<?xml version="1.0" encoding="UTF-8"?>
<p id="p0230">In managing critical ECoV cases with LVCI, the therapeutic dosages of low molecular weight heparin (LMWH) confirmed linked to a high frequency of thrombotic complexities in up to 1/3 of the cases 
 <xref rid="b0280" ref-type="bibr">[56]</xref>. Furthermore, nasal spray steroids and oral cobalamin prescribed in the management of acute CN I inflammation, yet anosmia endured during follow-up to more than 48 months. In one case report in which a triple antiviral therapy regimen incorporating subcutaneous pegylated interferon alpha-2a, high-dose oral ribavirin, and oral LPV/r, sensory symptoms seemed to recover over 6–7 months steadily 
 <xref rid="b0105" ref-type="bibr">[21]</xref>, 
 <xref rid="b0390" ref-type="bibr">[78]</xref>.
</p>
